Payment overview · 2025
General Payments
$5,525.93
82 reported records · 24 companies
Healthcare provider profile · identity verified
Daniel T Layish, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · ORLANDO, FL · NPI 1659350320
Verified facts
What the public records show
CMS Open Payments records show Daniel T Layish, M.D. received $5,525.93 in general payments during 2025 across 82 reported records.
Lilly USA, LLC accounted for 62.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arikayce, Nucala, Ofev, Opsumit, Tobi Podhaler, Trelegy Ellipta, Uptravi, Xywav, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Creon by this doctor in 2024.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Opsumit by this doctor in 2024.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSYNVI as an associated drug or biological on 4271 records involving 3021 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Opsynvi by this doctor in 2024.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UPTRAVI as an associated drug or biological on 21562 records involving 9341 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Uptravi by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 381 claims for Trelegy Ellipta by this doctor in 2024.
Insmed, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Arikayce as an associated drug or biological on 32500 records involving 8305 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Arikayce by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYWAV as an associated drug or biological on 19511 records involving 5343 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xywav by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adempas as an associated drug or biological on 14 records involving 2 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Adempas by this doctor in 2024.
VERTEX PHARMACEUTICALS INCORPORATED reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRIKAFTA as an associated drug or biological on 29 records involving 20 distinct recipient NPIs. Public Medicare Part D data also shows 475 claims for Trikafta by this doctor in 2024.
Viatris Specialty LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TOBI PODHALER as an associated drug or biological on 165 records involving 136 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Tobi Podhaler by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $3,468.43 | 62.8% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $274.80 | 5.0% | 15 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $269.45 | 4.9% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $243.90 | 4.4% | 18 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $221.58 | 4.0% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $170.65 | 3.1% | 3 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $144.76 | 2.6% | 6 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $135.13 | 2.5% | 4 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $105.28 | 1.9% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $102.80 | 1.9% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $82.32 | 1.5% | 4 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $53.27 | 1.0% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $33.08 | 0.6% | 2 | 2025 |
| Alcresta Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.21 | 0.5% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $25.58 | 0.5% | 1 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $22.10 | 0.4% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $21.27 | 0.4% | 1 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $20.08 | 0.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.95 | 0.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.74 | 0.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.81 | 0.3% | 1 | 2025 |
| Resmed Corp | Unresolved — no canonical attribution shown | $17.44 | 0.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.21 | 0.3% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $15.09 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,450.00 | 1 |
| Food and Beverage | $1,594.19 | 74 |
| Education | $281.74 | 6 |
| Consulting Fee | $200.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $3,468.43 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $274.80 | 15 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $269.45 | 7 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $221.58 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $178.94 | 2 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $170.54 | 11 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $144.76 | 6 | 2025 |
Source payment records
|
|||||
| TOBI PODHALER Normalized: tobi podhaler |
Drug | Viatris Specialty LLC | $142.96 | 2 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $135.13 | 4 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $102.80 | 4 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $86.01 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $73.36 | 7 | 2025 |
Source payment records
|
|||||
| Zemaira Normalized: zemaira |
Biological | Vifor Pharma, Inc. | $53.27 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $41.44 | 2 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $40.88 | 2 | 2025 |
Source payment records
|
|||||
| ALYFTREK Normalized: alyftrek |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $39.23 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $33.08 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $27.69 | 1 | 2025 |
Source payment records
|
|||||
| RELIZORB Normalized: relizorb |
Device | Alcresta Therapeutics, Inc. | $27.21 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $25.58 | 1 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| AIRSENSE Normalized: airsense |
Device | Resmed Corp | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| XOLAIR Normalized: xolair |
Drug | Novartis Pharmaceuticals Corporation | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $15.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Arikayce arikayce |
2025 | Arikayce | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUCALA nucala |
2025 | Nucala | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OFEV ofev |
2025 | Ofev | 2024 | 52 | exact normalized | Medicare Part D |
| OPSUMIT opsumit |
2025 | Opsumit | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TOBI PODHALER tobi podhaler |
2025 | Tobi Podhaler | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 381 | exact normalized | Medicare Part D |
| UPTRAVI uptravi |
2025 | Uptravi | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XYWAV xywav |
2025 | Xywav | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 104 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
75 | 17 |
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSYNVI open payments reported associated product |
CMS Open Payments — General Payments 4271 supporting records · 3021 recipient NPIs · example record 1174164038 |
Opsynvi · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | UPTRAVI open payments reported associated product |
CMS Open Payments — General Payments 21562 supporting records · 9341 recipient NPIs · example record 1174163984 |
Uptravi · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
104 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
128 | 39 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
381 | 89 |
| Insmed, Inc. Exact reporting entity; no affiliate inference |
2025 | Arikayce open payments reported associated product |
CMS Open Payments — General Payments 32500 supporting records · 8305 recipient NPIs · example record 1186254431 |
Arikayce · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | XYWAV open payments reported associated product |
CMS Open Payments — General Payments 19511 supporting records · 5343 recipient NPIs · example record 1234297700 |
Xywav · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | Adempas open payments reported associated product |
CMS Open Payments — General Payments 14 supporting records · 2 recipient NPIs · example record 1237996458 |
Adempas · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| VERTEX PHARMACEUTICALS INCORPORATED Exact reporting entity; no affiliate inference |
2025 | TRIKAFTA open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 20 recipient NPIs · example record 1213788219 |
Trikafta · 2024 Exact normalized brand match · 1 Part D row |
475 | 45 |
| Viatris Specialty LLC Exact reporting entity; no affiliate inference |
2025 | TOBI PODHALER open payments reported associated product |
CMS Open Payments — General Payments 165 supporting records · 136 recipient NPIs · example record 1238464081 |
Tobi Podhaler · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 480 | 184 |
| Trikafta | Elexacaftor/Tezacaftor/Ivacaft | 475 | 45 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 381 | 89 |
| Montelukast Sodium | Montelukast Sodium | 351 | 125 |
| Azithromycin | Azithromycin | 311 | 83 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 129 | 38 |
| Symbicort | Budesonide/Formoterol Fumarate | 128 | 39 |
| Breo Ellipta | Fluticasone/Vilanterol | 111 | 34 |
| Prednisone | Prednisone | 108 | 36 |
| Zenpep | Lipase/Protease/Amylase | 104 | 19 |
| Spiriva Respimat | Tiotropium Bromide | 100 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 18 |
| Creon | Lipase/Protease/Amylase | 75 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 72 | 30 |
| Ventolin Hfa | Albuterol Sulfate | 72 | 24 |
| Mirtazapine | Mirtazapine | 69 | 13 |
| Adempas | Riociguat | 68 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 34 |
| Alprazolam | Alprazolam | 63 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 62 | 15 |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 60 | 15 |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 56 | suppressed |
| Omeprazole | Omeprazole | 54 | 15 |
| Cayston | Aztreonam Lysine | 53 | 12 |
| Ofev | Nintedanib Esylate | 52 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 48 | 16 |
| Pertzye | Lipase/Protease/Amylase | 47 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 45 | 14 |
| Methylprednisolone | Methylprednisolone | 43 | 38 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Eszopiclone | Eszopiclone | 40 | 11 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 39 | 12 |
| Azelastine Hcl | Azelastine Hcl | 39 | 17 |
| Modafinil | Modafinil | 39 | suppressed |
| Gabapentin | Gabapentin | 37 | suppressed |
| Ursodiol | Ursodiol | 36 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 35 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | suppressed |
| Ambrisentan | Ambrisentan | 32 | suppressed |
| Opsumit | Macitentan | 32 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 32 | suppressed |
| Colistimethate | Colistin (Colistimethate Na) | 30 | suppressed |
| Uptravi | Selexipag | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Dulera | Mometasone/Formoterol | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 18 |
| Pulmicort Flexhaler | Budesonide | 21 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 20 | 13 |
| Famotidine | Famotidine | 20 | suppressed |
| Nucala | Mepolizumab | 20 | suppressed |
| Tadalafil | Tadalafil | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 15 |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Opsynvi | Macitentan/Tadalafil | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Ceftazidime | Ceftazidime | 15 | suppressed |
| Glassia | Alpha-1-Proteinase Inhibitor | 15 | suppressed |
| Adcirca | Tadalafil | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Arikayce | Amikacin Liposomal/Neb.Accessr | 14 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 14 | suppressed |
| Dupixent Pen | Dupilumab | 14 | suppressed |
| Tacrolimus | Tacrolimus | 14 | suppressed |
| Tobi Podhaler | Tobramycin | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Kalydeco | Ivacaftor | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Sirolimus | Sirolimus | 12 | suppressed |
| Tyvaso Dpi | Treprostinil | 12 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Xywav | Sodium,calcium,mag,pot Oxybate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,525.93 · 82 records | Lilly USA, LLC | AIRSENSE, ALYFTREK, AVYCAZ, Arikayce, BREZTRI, Brinsupri, DUPIXENT, JASCAYD, LUMRYZ, NUCALA, OFEV, OPSUMIT, PANCREAZE, RELIZORB, SMARTVEST, TOBI PODHALER, TRELEGY ELLIPTA, Tyvaso, UPTRAVI, Vest Therapy Und, WAKIX, WINREVAIR, WatchPATONE, XOLAIR, XYWAV, YUPELRI, ZENPEP, ZEPBOUND, Zemaira | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arikayce play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error